The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

CAR-T Meeting 2020 | Exciting data from the 2nd European CAR T-Cell Meeting

Name: Exciting data from the 2nd European CAR T-Cell Meeting
Uploaded: 2020-01-30T00:00:00.000Z
Duration: 56 s
Description: Robin Sanderson, MBChB, MRCP, FRCPath, King’s College Hospital NHS Foundation Trust, London, UK, outlines the updates presented at the 2nd European CAR T-Cell Meeting in Sitges, Spain. Dr Sanderson highlights the ZUMA-1 trial and axicabtagene ciloleucel for mantle cell lymphoma. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.

Robin Sanderson • 30 Jan 2020

CAR-T Meeting 2020

Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T Lisocabtagene maraleucel

ZUMA-1

Robin Sanderson, MBChB, MRCP, FRCPath, King’s College Hospital NHS Foundation Trust, London, UK, outlines the updates presented at the 2nd European CAR T-Cell Meeting in Sitges, Spain. Dr Sanderson highlights the ZUMA-1 trial and axicabtagene ciloleucel for mantle cell lymphoma. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.